BIO-FD&C Q1 2026 Results: Revenue and Profit Decline, Solid Financial Position

Q1 2026 revenue: 3,998 million won, down 7.5% YoY (Q1 2025: 4,323 million won)
Operating profit: 1,026 million won, down 28.7% YoY (Q1 2025: 1,440 million won); Net income: 1,161 million won, down 28.8% YoY
Debt ratio improved to 5.0% (end-2025: 5.2%), net cash of 11,627 million won
R&D expenses: 279 million won (6.97% of sales), decreased from prior year's 407 million won (9.42%)
Holds 185 patents; competitive in microneedle patches and plant cell platform technology
No dividend paid; holds 166,751 treasury shares